Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03644264
Other study ID # PA-CL-CHINA-01
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date August 31, 2018
Est. completion date August 21, 2020

Study information

Verified date May 2021
Source Vifor Fresenius Medical Care Renal Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the efficacy of PA21 in comparison with sevelamer carbonate (Renvela®) in lowering and maintaining serum phosphorus in adult Chinese subjects with CKD on dialysis after 12 weeks of treatment.


Description:

Primary Objective is to evaluate the efficacy of PA21 in comparison with sevelamer carbonate (Renvela®) in lowering and maintaining serum phosphorus in adult Chinese subjects with CKD on dialysis after 12 weeks of treatment. In addition , secondary objectives include evaluating the efficacy of PA21 and sevelamer carbonate over time as the percentage of subjects with serum phosphorus within the target range of 1.13 to 1.78 mmol/l (3.5 to 5.5 mg/dl) and to compare the safety and tolerability of PA21 versus sevelamer carbonate (Renvela®). In total, 286 patients (143 patients to PA21 treatment and 143 patients to sevelamer carbonate treatment) will be randomised with a screening period: up to 4 weeks and a washout period of up to 3 weeks. Treatment period (total duration 12 weeks) will include a dose titration period and a maintenance period of an open-label, active-controlled comparison of PA21 versus sevelamer carbonate for 4 weeks. The primary efficacy assessment will be a non-inferiority assessment of the 2 groups of subjects at Week 12 in terms of serum phosphate lowering capability. There will be a follow-up period of 30 days after last dosing. The investigational treatments will be a PA21 dose group of PA21 chewable tablets standardised to contain 500 mg of iron. PA21 contains approximately 20% m/m of elemental iron. All doses of PA21 are expressed in mg of iron. The Starting dose will be 1,500 mg/day (3 tablets/day (1 tablet per meal)). Dose increases or decreases of 500 mg/day (1 tablet/day) are permitted , provided a subject has been receiving that dose for a minimum of 2 weeks and for safety or tolerability reasons at any time. The maximum dose of PA21 will be 3,000 mg/day (6 x 500 mg tablets/day) and the minimum dose will be 1,000 mg/day (2 x 500 mg tablets/day). The active control is sevelamer carbonate, Renvela®, tablets, containing 800 mg of sevelamer carbonate. The starting dose will be 2.4 g/day (3 tablets/day). Dose increases or decreases of 2.4 g/day (3 tablets/day (1 tablet per meal)) are permitted, provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time. The maximum dose of sevelamer carbonate will be 14.4 g/day (18 tablets/day) and the minimum dose will be 2.4 g/day (3 tablets/day).


Recruitment information / eligibility

Status Completed
Enrollment 286
Est. completion date August 21, 2020
Est. primary completion date August 21, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Chinese subjects receiving either maintenance haemodialysis (HD) or peritoneal dialysis (PD) for at least 12 weeks prior to screening. No home HD or nocturnal HD (overnight stay at site) will be allowed 2. Subjects with a history of hyperphosphataemia (HP). 3. Subjects with serum phosphorus levels >5.5 mg/dl (>1.78 mmol/l) at screening or during the washout period. 4. Male and female adult subjects (aged =18 years at time of consent). 5. Subjects with the ability to understand the requirements of the study and abide by the study restrictions, and who agree to return for the required assessments (in the Investigator's opinion). 6. Subject (or legally acceptable representative) has provided the appropriate written informed consent. Subject must provide written informed consent before any study-specific procedures are performed including screening procedures. Exclusion Criteria: 1. Subjects with intact parathyroid hormone (iPTH) levels >800 ng/l (>800 pg/ml or 88 pmol/l) at screening. Subjects with iPTH >600 ng/l (>600 pg/ml or 66 pmol/l) at screening must be considered stable (in the Investigator's opinion). 2. Subjects with planned or expected parathyroidectomy within the next 6 months (in the Investigator's opinion). 3. Subjects on peritoneal dialysis (PD) with a history of peritonitis in the last 3 months or =3 episodes in the last 12 months. 4. Subjects with serum total calcium >10.5 mg/dl (>2.6 mmol/l) or <7.6 mg/dl (1.9 mmol/l) at screening. 5. Subjects with: - Any history of major gastrointestinal (GI) surgery likely to influence the outcome of treatment with PBs - Clinically significant, active GI disorders (e.g., active peptic ulcer, Crohn's disease, colitis ulcerative, irritable bowel syndrome, intestinal motility disorder (symptomatic gastroparesis (during treatment or untreated), intestinal obstruction, moderate/severe constipation (including persistent symptoms with regular use of laxatives or enemas and limitations in activities of daily living), intestinal pseudo-obstruction, megacolon, mechanical obstruction)) or any GI disorders under medical treatment. - Clinically significant, active hepatic disorders or any hepatic disorder under medical treatment 6. Subjects currently with (in the Investigator's opinion): - Swallowing difficulties/dysphagia - Estimated life expectancy of less than 12 months - Anticipated renal transplantation during study participation 7. Subjects with known seropositivity to human immunodeficiency virus or positive HIV test at screening. 8. Subjects with active/current fulminant hepatitis B infections and/or hepatitis C virus ribonucleic acid positivity at screening. 9. Subjects with a history of haemochromatosis or other iron accumulation disorders that might lead to iron overload. 10. Subjects with serum ferritin >800 mcg/l (1,797.6 pmol/l) or transferrin saturation (TSAT) >50% at screening. 11. Subjects with raised alanine aminotransferase or aspartate aminotransferase >3 times the upper limit of the normal range at screening. 12. Subject is taking any prohibited medication(s) which cannot be stopped at least one week before study treatment start. Prohibited medications include: oral calcium supplements, any drugs/agents having a phosphate binding action that contain aluminium, magnesium or calcium (apart from hyperkalaemia drugs), phosphate binders in addition to sevelamer carbonate), nicotinamide, oral iron products, oral vitamins containing iron and other oral iron containing supplements (See Section 7.7). 13. Subject has known hypersensitivity and/or intolerance to any of the study products to be administered. 14. Subject has previously been randomised into this study. 15. Subject is currently enrolled in or has completed any other investigational device or drug study <30 days prior to screening, or is receiving other investigational agent(s). 16. Subjects who are pregnant (e.g., positive human chorionic gonadotropin test) or breastfeeding. 17. Subjects of childbearing potential, not using adequate contraceptive precautions must agree to use a highly effective method of birth control during the study and for 1 month after the last dose of study medication. 18. Subject has a history of drug or alcohol abuse within 2 years prior to screening. 19. Subject has a significant medical conditions or anticipated need for major surgery during the study, which (in the Investigator's opinion), may be associated with increased risk to the subject, or may interfere with study assessments or outcomes, or the ability to provide informed consent or comply with study procedures.

Study Design


Intervention

Drug:
PA21
sucroferric oxyhydroxide is a mixture of polynuclear iron(III)-oxyhydroxide (about 33% m/m), sucrose (about 30% m/m), and starches (about 28% m/m) and contains =10% m/m water.
sevelamer carbonate
sevelamer carbonate tablets containing 800 mg of sevelamer carbonate.

Locations

Country Name City State
China Southern Medical University Nanfang Hospital Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Vifor Fresenius Medical Care Renal Pharma

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serum phosphorus (mmol/l ) Change from baseline in serum phosphorus levels at Week 12: comparison between PA21 group and sevelamer carbonate group. baseline and 12 weeks
Secondary Serum phosphorus (mmol/l ) Serum phosphorus levels at each time point and change from baseline (BL) baseline, weeks 1, 2, 4, 6, 8, 12
Secondary Serum phosphorus (mmol/l) % of subjects with serum phosphorus within 1.13 to 1.78 mmol/l baseline, weeks 1, 2, 4, 6, 8, 12
Secondary Adverse events (AEs) Frequency of AEs determined by seriousness, severity and relatedness to study drugs baseline, weeks 1, 2, 4, 6, 8, 12
Secondary Diarrhoea. Frequency of AE of special interest - diarrhoea. baseline, weeks 1, 2, 4, 6, 8, 12
Secondary Withdrawals due to AEs Percentage of withdrawals due to AEs baseline, weeks 1, 2, 4, 6, 8, 12
Secondary Serum calcium (mmol/l) Serum total calcium levels at each time point and change from baseline baseline, weeks 1, 2, 4, 6, 8, 12
Secondary Hypercalcemia (mmol/l) Percentage of subjects that develop at least 1 episode of sustained hypercalcaemia (>10.0 mg/dl; >2.5 mmol/l) during study participation baseline, weeks 1, 2, 4, 6, 8, 12
Secondary Serum iPTH (pg/ml) Serum iPTH levels at specified time points and change from baseline baseline, weeks 8, 12
Secondary Serum iron (mcg/dl) Serum iPTH levels at specified time points and change from baseline baseline, weeks 4, 8, 12
Secondary Serum ferritin (mcg/l) Serum ferritin levels at specified time points and change from baseline baseline, weeks 4, 8, 12
Secondary Serum transferrin (mcg/dl) Serum transferrin measured at specified timepoints baseline, weeks 4, 8, 12
Secondary Transferrin saturation (TSAT) (%) TSAT measured at specified timepoints baseline, weeks 4, 8, 12
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT02237534 - Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia Phase 4
Completed NCT01252771 - Phosphate Kinetic Modeling 2 Phase 4
Completed NCT01187628 - Long-term Study in Chronic Kidney Disease (Extension From Study 14817) Phase 3
Unknown status NCT01245517 - The Influence of Dietary Phosphorus Education Program on Nutritional Status and Serum Phosphate Level Among Hemodialysis Patient N/A
Completed NCT00506441 - A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia Phase 3
Recruiting NCT04440696 - To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder Phase 1/Phase 2
Completed NCT01976572 - Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects Phase 1
Completed NCT01742585 - A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Phase 3
Completed NCT01191255 - A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis Phase 3
Completed NCT01003223 - Phosphate Kinetic Modeling N/A
Completed NCT00505037 - A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis Phase 2
Completed NCT00508885 - The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients Phase 1/Phase 2
Completed NCT04551300 - A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients Phase 2
Completed NCT01955876 - Fosrenol Post-marketing Surveillance in Japan N/A
Completed NCT04579315 - Long-term Effects of the New Nordic Renal Diet in Patients With Moderate Chronic Kidney Disease N/A
Completed NCT03861247 - Individualized Treatment of Hyperphosphatemia in Maintenance Hemodialysis Patients Phase 3
Terminated NCT01725113 - Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol Phase 4
Recruiting NCT01238588 - The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan N/A
Completed NCT00542815 - A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Phase 3
Completed NCT04549597 - Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia Phase 4